Skip to main content
SpringerLink
Log in

Tenofovir disoproxil fumarate (TDF) plus ritonavir-boosted protease inhibitor (PI) regimens appear to be associated with greater renal function decline

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Goicoechea M, Liu S, Best B, Sun S, Jain S, Kemper C, Witt M, Diamond C, Haubrich R, Louie S, California Collaborative Treatment Group 578 Team.Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. Journal of Infectious Diseases 197: 102-108, No. 1, 1 Jan 2008

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tenofovir disoproxil fumarate (TDF) plus ritonavir-boosted protease inhibitor (PI) regimens appear to be associated with greater renal function decline. React. Wkly. 1188, 4 (2008). https://doi.org/10.2165/00128415-200811880-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-200811880-00008

Keywords

Search

Navigation